Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

0 of 8 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(44.4%)

Phase 3

3(33.3%)

Phase 2

2(22.2%)

9Total

Phase 1(4)

Phase 3(3)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT01581450Phase 1Completed

Hyperalgesia and Pain

Role: collaborator

NCT02869243Phase 1Completed

A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients

Role: collaborator

NCT00325507Phase 2Completed

Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma

Role: collaborator

NCT00083941Phase 2Completed

A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer

Role: collaborator

NCT03661489Phase 3Completed

Efficacy and Safety of Remimazolam (CNS7056) Compared to Propofol for Intravenous Anesthesia During Elective Surgery

Role: collaborator

NCT02572635Phase 1Completed

A Phase I Study to Evaluate the Safety and Immunogenicity of PnuBioVax

Role: collaborator

NCT02243683Phase 1Completed

Safety Study of Immune System Modulator for Autoimmune Diseases

Role: collaborator

NCT01420159Phase 3Completed

Efficacy and Safety of Methoxyflurane (Penthrox) for the Treatment of Acute Pain in Minor Trauma

Role: collaborator

NCT00358566Phase 3Terminated

GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer

Role: collaborator

All 9 trials loaded